Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual GLP-1/glucagon agonist approaching clinical use.
Key findingSystematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual
What the researchers found
Systematic review of survodutide efficacy and safety for obesity consolidates evidence for this dual GLP-1/glucagon agonist approaching clinical use.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center), 38(4), 514-522
Citation
Awad, Abdelaziz A; Abdrabou Abouelmagd, Alaa; Mohammed, Fatma; Elettreby, Abdelrahman M; Mahmoud Marey, Mohamed; Aldemerdash, Mohamed A; Soliman, Samar M; Belal, Mohamed Mohamed; Abosheaishaa, Hazem. (2025). Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.. Proceedings (Baylor University. Medical Center), 38(4), 514-522. https://doi.org/10.1080/08998280.2025.2480512